Page last updated: 2024-12-05

pentazocine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pentazocine is a synthetic opioid analgesic with mixed agonist-antagonist properties. It binds to the μ-opioid receptor as an antagonist and to the κ-opioid receptor as an agonist. Pentazocine is typically administered intravenously or intramuscularly for the management of moderate to severe pain, but it is also available in oral and nasal formulations. Pentazocine was first synthesized in the 1960s and was initially marketed as a safer alternative to morphine. However, its potential for abuse and its side effects, including respiratory depression and hallucinations, led to concerns about its use. In recent years, research has focused on the potential of pentazocine as a treatment for chronic pain, particularly neuropathic pain. Its mixed agonist-antagonist properties may offer benefits over traditional opioid agonists, such as reduced tolerance and dependence. Studies have explored its efficacy in treating pain associated with conditions such as diabetic neuropathy, postherpetic neuralgia, and cancer-related pain.'

Pentazocine: The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID441278
CHEMBL ID560
CHEBI ID7982
SCHEMBL ID2492
MeSH IDM0016179
PubMed CID4736
CHEMBL ID100116
CHEBI ID182080
SCHEMBL ID2493
MeSH IDM0016179

Synonyms (133)

Synonym
gtpl1606
l-pentazocine
(2r,6r,11r)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
(2r*,6r*,11r*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol
pentazocina [dcit]
hsdb 3150
3-(3-methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-
win 20228
2-dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan
kf-1820
2-(3,3-dimethylallyl)cyclazocine
sosegon
einecs 206-634-6
sosigon
1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol
pentazocinum [inn-latin]
nih 7958
2'-hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
fortalin
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11r*)-
nsc 107430
pentagin
pentazocin
2-(3,3-dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan
ii-c-2
pentazocine
C07421
359-83-1
DB00652
fortral (tn)
D00498
pentazocine (jp17/usp/inn)
(+)-pentazocine
chebi:7982 ,
CHEMBL560 ,
win 20,228
nih-7958
win-20228
pentazocine civ
dl-pentazocine
7488-49-5
(2r,6r,11r)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-2,6-methano-3-benzazocin-8-ol
levopentazocine
6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
(2r,6r,11r)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
pentazocine (+)
(6r,11s)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(pentazocine)
pentazocine,(+/-)
bdbm50001028
pentazocine (-)
rel-(2r,6r,11r)-6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
pentazocine [usan:usp:inn:ban:jan]
cis-(+-)-pentazocine
rp4a60d26l ,
(2alpha,6alpha,11r*)-(1)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol
pentazocinum
pentazocina
einecs 244-593-6
unii-rp4a60d26l
(+-)-pentazocine
pentazocaine
FT-0673607
(-)-.alpha.-pentazocine
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2r,6r,11r)-
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, cis-(-)-
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-, (2r,6r,11r)-
pentazocine [ep impurity]
pentazocine [mi]
pentazocine [who-dd]
pentazocine [mart.]
pentazocine [usan]
pentazocine [vandf]
pentazocine civ [usp-rs]
pentazocine, (-)-
unii-768dq5a5ai
768dq5a5ai ,
cis-(-)-pentazocine
pentazocine [ep monograph]
pentazocine 2r,6r,11r-form [mi]
pentazocine [usp monograph]
pentazocine, l-
pentazocine [hsdb]
pentazocine [jan]
pentazocine 2r,6r,11r-form
(+/-)-pentazocine
pentazocine [inn]
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-, (2r,6r,11r)-rel-
cis-(+/-)-pentazocine
(-)-alpha-pentazocine
SCHEMBL2492
DTXSID7023433
(1r,9r,13r)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0^{2,7}]trideca-2,4,6-trien-4-ol
(1r,9r,13r)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
Q415793
359-83-1 (free base)
(2r,6r,11r)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methanobenzo[d]azocin-8-ol
(1r,9r,13r)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0?,?]trideca-2,4,6-trien-4-ol
(1r,9r,13r)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0?,?]trideca-2(7),3,5-trien-4-ol
55643-30-6
PDSP1_000673
6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol (pentazocine)
1,13-dimethyl-10-(3-methyl-2-butenyl)-(1r,9r,13r)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol(pentazocine)
6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; lactate
(pentazocine) 6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2 ,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
bdbm50032403
(pentazocine)2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid
2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(15s)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol(pentazocine)
(pentazocine) 6,11-dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol
1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
CHEBI:182080
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2.alpha.,6.alpha.,11r*)-
liticon
PDSP2_000663
fortalgesic
nsc-107430
algopent (free base)
fortral
talwin
L001017
CHEMBL100116 ,
einecs 259-735-2
1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol
soseton
talwan
SCHEMBL2493
dl-2'-hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan
2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2r,6r,11r)-rel-
VOKSWYLNZZRQPF-UHFFFAOYSA-N
(.+/-.)-pentazocine
DTXSID30859346
1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-2,6-methano-3-benzazocin-8-ol

Research Excerpts

Toxicity

A combination of propofol via TCI pump, bolus injection of pentazocine as needed, and BIS monitoring was a safe and effective procedure for peroral DBE.

ExcerptReferenceRelevance
" We conclude that SPV done as an outpatient procedure is safe in expert hands and is economical."( Splenoportovenography in portal hypertension: a safe outpatient procedure.
Bambery, P; Chawla, YK; Dilawari, JB; Kaur, U; Raju, GS, 1990
)
0.28
" A similar number of adverse reactions occurred in each group but patients receiving pentazocine seemed to be more likely to develop reactions affecting the central nervous system, an important point in the therapy of ill, but often ambulant patients."( Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain.
Scheef, W, 1987
)
0.27
"Approximately equianalgesic oral doses of codeine, an oxycodone compound resembling Percodan, and pentazocine were compared for adverse effects in a double-blind, randomized study of four doses of each drug given over two days to 247 postsurgical patients with pain."( Adverse effects of commonly ordered oral narcotics.
Hopper, M; Kantor, TG; Laska, E, 1981
)
0.26
" However, an acceleration of behavioral despair in the Porsolt test similar to that observed in the IM group was observed in the COCA group after the disappearance of the acute toxic symptoms (5 hours after the COCA treatment)."( Stress-related behavioral alterations accompanying cocaine toxicity: the effects of mixed opioid drugs.
Hayase, T; Yamamoto, K; Yamamoto, Y, 2000
)
0.31
" This study examined the structure and predictive validity of somatic and cognitive/affective side-effect profiles of morphine and pentazocine using the Somatic Side Effects Questionnaire and the Cognitive and Affective Side Effects Questionnaire."( Cognitive-affective and somatic side effects of morphine and pentazocine: side-effect profiles in healthy adults.
Campbell, CM; Fillingim, RB; Glover, TL; Hastie, BA; Riley, JL; Staud, R, 2010
)
0.36
" These drug-related side-effect profiles were linked with analgesic responses."( Cognitive-affective and somatic side effects of morphine and pentazocine: side-effect profiles in healthy adults.
Campbell, CM; Fillingim, RB; Glover, TL; Hastie, BA; Riley, JL; Staud, R, 2010
)
0.36
" However, no patient experienced any serious adverse events."( An effective and safe sedation technique combining target-controlled infusion pump with propofol, intravenous pentazocine, and bispectral index monitoring for peroral double-balloon endoscopy.
Harada, K; Hiraoka, S; Hori, K; Inokuchi, T; Iwamuro, M; Kanzaki, H; Kawahara, Y; Kawano, S; Kouno, Y; Miura, K; Okada, H; Yamamoto, K, 2015
)
0.42
"A combination of propofol via TCI pump, bolus injection of pentazocine as needed, and BIS monitoring was a safe and effective procedure for peroral DBE."( An effective and safe sedation technique combining target-controlled infusion pump with propofol, intravenous pentazocine, and bispectral index monitoring for peroral double-balloon endoscopy.
Harada, K; Hiraoka, S; Hori, K; Inokuchi, T; Iwamuro, M; Kanzaki, H; Kawahara, Y; Kawano, S; Kouno, Y; Miura, K; Okada, H; Yamamoto, K, 2015
)
0.42

Pharmacokinetics

Pentazocine and acetylsalicylic acid were tested in 14 human volunteers. The pharmacokinetic parameters for the volume of distribution at steady state (V dss) and during the beta-phase are statistically significant increased during the night.

ExcerptReferenceRelevance
" We assessed the effect of pentazocine and acetylsalicylic acid on these parameters in 14 human volunteers and related the effects to the pharmacokinetic parameters of the drugs measured at the same time."( Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to pharmacokinetic parameters.
Brune, K; Hummel, C; Kobal, G; Nuernberg, B, 1990
)
0.28
"A new technique, the area method, is derived for the determination of partition coefficients for both blood-flow limited and membrane limited physiological pharmacokinetic models."( Area method for the estimation of partition coefficients for physiological pharmacokinetic models.
Gallo, JM; Lam, FC; Perrier, DG, 1987
)
0.27
"Various pharmacokinetic parameters--disposition half-life, t1/2,z, metabolic clearance CLm, volume of distribution V, intrinsic clearance of unbound drug CLuint, and unbound volume of distribution of tissues (distributive tissue volume/fraction of drug in tissue unbound, VT/fuT--are compared in rat and human for nine weakly acidic drugs, phenytoin, hexobarbital, pentobarbital, phenylbutazone, warfarin, tolbutamide, valproate, phenobarbital, and amobarbital, and six weakly basic drugs, quinidine, chlorpromazine, propranolol, pentazocin, antipyrine, and diazepam."( Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.
Hanano, M; Iga, T; Sawada, Y; Sugiyama, Y, 1985
)
0.27
" The pharmacokinetic parameters for the volume of distribution at steady state (V dss) and during the beta-phase (V d beta) and the biological half-life (t 1/2 beta) are statistically significant increased during the night, documenting circadian rhythm for the disposition of pentazocine."( Chronopharmacokinetics of pentazocine in the beagle dog.
Bykadi, G; Lücker, PW; Norman, EJ; Ritschel, WA, 1980
)
0.26
"In order to assess quantitatively the pharmacodynamic process of pentazocine (PTZ), time courses of its plasma concentration and of the occupation of specific opioid receptors in the brain were investigated after intravenous (i."( Pharmacokinetics of pentazocine and its occupancy of opioid receptors in rat brain.
Hanano, M; Nishino, J; Suganuma, T; Suzuki, T, 1997
)
0.3
" Here we present a unique, generic, physiologically based pharmacokinetic (PBPK) model and demonstrate its application to the estimation of rat plasma pharmacokinetics, following intravenous dosing, from in vitro data alone."( Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma.
Brightman, FA; Leahy, DE; Searle, GE; Thomas, S, 2006
)
0.33

Compound-Compound Interactions

Study was to determine whether polarized arrest using adenosine/lidocaine cold crystalloid cardioplegia in combination with the hibernation inductor pentazocine would give satisfactory myocardial protection.

ExcerptReferenceRelevance
"A new method based on liquid-liquid-liquid microextraction combined with electrospray ionization-ion mobility spectrometry (LLLME-ESI-IMS) was used for the determination of pentazocine in urine and plasma samples."( Hollow fiber-based liquid-liquid-liquid microextraction combined with electrospray ionization-ion mobility spectrometry for the determination of pentazocine in biological samples.
Jafari, MT; Saraji, M; Sherafatmand, H, 2010
)
0.36
"The purpose of this study was to determine whether polarized arrest using adenosine/lidocaine cold crystalloid cardioplegia in combination with the hibernation inductor δ-opioid receptor agonist pentazocine would give satisfactory myocardial protection rather than using depolarized supranormal potassium cardioplegia, supranormal potassium cardioplegia with pentazocine, or adenosine/lidocaine cardioplegia."( The myocardial protection of polarizing cardioplegia combined with delta-opioid receptor agonist in swine.
Chen, C; Dong, P; Hou, X; Wu, T; Yang, J, 2011
)
0.37

Bioavailability

The effect of moderate cirrhosis on the bioavailability and systemic clearance of three model analgesic compounds (pethidine, pentazocine, and salicylamide) with substantial first-pass metabolism was examined in 8 cirrhotic subjects and 4 agematched healthy controls. The low solubility and low oral bioavailability due to extensive first pass metabolism make Pentazocines an ideal candidate for oral and topical sustained release delivery.

ExcerptReferenceRelevance
"The effect of moderate cirrhosis on the bioavailability and systemic clearance of three model analgesic compounds (pethidine, pentazocine, and salicylamide) with substantial first-pass metabolism was examined in 8 cirrhotic subjects and 4 agematched healthy controls."( Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis.
Blaschke, TF; Gregory, PB; Meffin, PJ; Neal, EA, 1979
)
0.26
"The bioavailability of oral pentazocine was studied in 5 healthy volunteers."( Bioavailability and first-pass metabolism of oral pentazocine in man.
Boréus, LO; Ehrnebo, M; Lönroth, U, 1977
)
0.26
"The relative bioavailability and pharmacokinetics of a combination product containing pentazocine and acetaminophen were studied in 20 healthy human males."( Relative bioavailability and pharmacokinetics: a combination of pentazocine and acetaminophen.
Benziger, DP; Edelson, J; Fritz, AK; Park, GB; Peterson, JE, 1984
)
0.27
"We studied the bioavailability and disposition kinetics of pethidine and pentazocine in patients with alcoholic cirrhosis and age-matched healthy subjects."( Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver.
Benowitz, NL; Jacob, P; Pond, SM; Tong, T, 1980
)
0.26
" In an attempt to synthesize analogs of cyclazocine with increased bioavailability and varying kappa agonist and partial mu agonist properties, a series of 8-amino derivatives of cyclazocine were synthesized."( Partial opioids. Medications for the treatment of pain and drug abuse.
Bidlack, JM; McLaughlin, JP; Wentland, MP, 2000
)
0.31
"Bioadhesive chitosan microspheres (Ms) of pentazocine (Pz) for intranasal systemic delivery were prepared with the aim of avoiding the first pass effect, and thus improving the bioavailability and achieving sustained and controlled blood level profiles, as an alternative therapy to injection and to obtain improved therapeutic efficacy in the treatment of chronic pain such as cancer, trauma and post-operative pain, etc."( Chitosan based pentazocine microspheres for intranasal systemic delivery: development and biopharmaceutical evaluation.
Mishra, B; Rani, M; Sankar, C; Srivastava, AK, 2001
)
0.31
" The low solubility and low oral bioavailability due to extensive first pass metabolism make Pentazocine as an ideal candidate for oral and topical sustained release delivery."( Enhancement of Dissolution and Skin Permeability of Pentazocine by Proniosomes and Niosomal Gel.
Jabar, A; Khan, A; Madni, A; Mahmood, MA; Rahim, MA; Rehman, M; Shah, A; Shah, H; Tahir, N, 2018
)
0.48
" In this study, PTZ loaded Ethyl cellulose microsphere has been formulated for sustained release and improved bioavailability of PTZ."( Statistically optimized pentazocine loaded microsphere for the sustained delivery application: Formulation and characterization.
Bashir, S; Jabar, A; Jan, N; Khan, A; Khan, S; Madni, A; Rahim, MA; Shah, H; Tahir, N; Usman, F, 2021
)
0.62

Dosage Studied

The comparison drug pentazocine and placebo were administered in the same dosage regimen. There was no significant between-group difference in the total pentazOCine dosage during the first 7 days. The dose-response curves to naloxone obtained in tissues individually exposed to different opiates showed that their relative potency in increasing sensitivity to n aloxone was as follows.

ExcerptRelevanceReference
"Twenty opioids have been subdivided into four classes by using flurothyl-induced seizures in rats to measure dose-response relationships, stereospecificity, naloxone sensitivity, and tolerance-cross-tolerance."( Classification of opioids on the basis of change in seizure threshold in rats.
Adler, MW; Cowan, A; Geller, EB, 1979
)
0.26
" Dose-response curves were determined for the effects of morphine (0."( Comparison of the effects of morphine, pentazocine, cyclazocine and amphetamine on intracranial self-stimulation in the rat.
Holtzman, SG, 1976
)
0.26
"Pentazocine, a systemic analgesic, can be utilized in local analgesic and intravenous techniques to provide better operating conditions in difficult cases, a reduction in the dosage of other agents employed, and a smoother recovery period."( The value of associating pentazocine with drugs used in accepted intravenous techniques.
Armstrong, PJ, 1975
)
0.25
" There were at least 50 patients in each of the five dosage groups."( Butorphanol and pentazocine in patients with severe postoperative pain.
Caruso, FS; Dobkin, AB; Eamkaow, S, 1975
)
0.25
" The discriminable ED50 values for both pentazocine and morphine were estimated from dose-response curves and when given in combination (pentazocine ED50 + morphine ED50), more drug-related responding occurred than occurred after either drug (ED50) alone."( Stimulus properties of the narcotic antagonist pentazocine: similarity to morphine and antagonism by naloxone.
Appel, JB; Greenberg, I; Kuhn, DM, 1976
)
0.26
" In cases with heart disease and elderly subjects, a lower dosage or omission of atropine was common."( [Manipulation, premedication, and chemoprophylaxis for fiberoptic bronchoscopy].
Hasegawa, Y; Ogasawara, T; Saka, H; Shimokata, K; Watanabe, A, 1992
)
0.28
" When ischemic animals were administered the multiple dosing regimen of (+)SKF 10,047, no hypothermic effect was noted in the temporalis muscle over 4 hours' postischemia."( Neuroprotective effects of SKF 10,047 in cultured rat cerebellar neurons and in gerbil global brain ischemia.
Feuerstein, G; Gagnon, RC; Gu, JL; Lysko, PG; Yue, TL, 1992
)
0.28
" Concurrent dosing of pentazocine (2 mg/kg, IP) and tripelennamine (2."( Potentiation of pentazocine conditioned place preference by tripelennamine in rats.
Masukawa, Y; Misawa, M; Shiozaki, Y; Suzuki, T, 1991
)
0.28
" The treatment groups revealed no differences in baseline pain and the dosage was similar in each."( Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain.
Scheef, W, 1987
)
0.27
" Nalbuphine was not consistently identified as either pentazocine or hydromorphone and produced relatively flat dose-response functions on most of the subjective effect measures."( Drug discrimination in human postaddicts: agonist-antagonist opioids.
Bickel, WK; Bigelow, GE; Liebson, IA; Preston, KL, 1989
)
0.28
" The main advantages were not only continuous pain relief despite the fact that the nonepidural control group required more than twice the dosage of morphine derivatives; also, the respiratory and pain-related recovery time was reduced."( [Catheter epidural analgesia in serial rib fractures].
Glatzl, A; Poigenfürst, J; Sandtner, W; Thonke, N, 1989
)
0.28
" Complete dose-response data for morphine, heroin, etorphine, d- and l-ethylketazocine, d- and l-pentazocine, and d- and l-N-allylnormetazocine revealed a predominant response of hyperthermia."( Body temperature effects of opioids in rats: intracerebroventricular administration.
Adler, MW; Geller, EB; Rowan, CH, 1986
)
0.27
"5 mg/kg) allowed for a significant reduction in the mean dosage of midazolam required to produce satisfactory sedation when compared with trials where midazolam was used alone."( New intravenous sedative combinations in oral surgery: a comparative study of nalbuphine or pentazocine with midazolam.
Hook, PC; Lavery, KM, 1988
)
0.27
" After 12 generations of selective breeding, the high antinociceptive response line exhibited about 7 times steeper dose-response curve than did the low antinociceptive response line whereas only small differences were seen with saline alone."( Selective breeding for levorphanol-induced antinociception on the hot-plate assay: commonalities in mechanism of action with morphine, pentazocine, ethylketocyclazocine, U-50488H and clonidine in mice.
Belknap, JK; Danielson, PW; Laursen, SE; Noordewier, B, 1987
)
0.27
" All eight drugs produced dose-related decreases in response rates, and the buprenorphine dose-response curve was more shallow and not parallel to the others."( Comparison of opioid self-injection and disruption of schedule-controlled performance in the baboon.
Brady, JV; Griffiths, RR; Lukas, SE, 1986
)
0.27
" Implications of change in clearance and half-life on dosage regimen design are discussed."( The effect of age on the pharmacokinetics of pentazocine.
Frederick, KA; Hoffmann, KA; Ritschel, WA; Wetzelsberger, N; Willig, JL, 1986
)
0.27
" Moreover, also the dosage (number of capsules/day) was similar in both groups."( [Flupirtine in patients with cancer pain].
Scheef, W; Wolf-Gruber, D, 1985
)
0.27
" Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine."( Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
Botsford, KB; Kabins, SA; Nathan, CR; Weinstein, RA, 1985
)
0.27
" The comparison drug pentazocine and placebo were administered in the same dosage regimen (a single dose of pentazocine amounting to 50 mg)."( [The effect of the analgesic flupirtine on automobile driving].
Biehl, B, 1985
)
0.27
" 24 had received pentazocine after discharge; two required an increase in dosage and four expressed a preference for pentazocine."( Medicines evaluation and monitoring group: central nervous system effects of pentazocine.
Campbell, C; Davidson, JF; Gallon, SC; Henney, E; McAllion, S; Moir, DC; Wood, AJ, 1974
)
0.25
" Rats were dosed continuously with morphine hydrochloride by giving a daily dose through tubes connected to small, subcutaneously implanted reservoirs."( An implanted reservoir of morphine solution for rapid induction of physical dependence in rats.
Goode, PG, 1971
)
0.25
" It is found that the graft of f tau vs log [D] exhibits features similar to the in vivo dose-response curves for the drugs."( Drug affinities for the agonist and antagonist states of the opioid receptor.
Barsuhn, C; Cheney, BV; Lahti, RA, 1982
)
0.26
" At the dosage applied no major respiratory or circulatory effects were observed in the patients."( [Mr 1268--a new furylmethyl-substituted benzomorphan. Comparison of its effects with pentazocine and placebo in a double-blind study].
Behrendt, W; Conrad, H; Richter, M; Veit, G, 1983
)
0.27
" Although morphine (ID50 = 4 micrograms) was a very potent analgesic when given intracerebroventricularly, very shallow dose-response curves were obtained with the other substances which promoted less than 30% of inhibition at doses up to 250 micrograms."( The peripheral analgesic effect of morphine, codeine, pentazocine and d-propoxyphene.
Ferreira, SH; Lorenzetti, BB; Molina, N; Vettore, O, 1983
)
0.27
" The low toxicity and the absence of the side effects typical to narcotic analgesics suggest to study the analgesic effects of ASL with higher dosage schedules or different administrations in order to increase the analgesic potency of the drug in the post-operative period."( [Lysine acetylsalicylate in the control of postoperative pain in surgery of the upper abdomen].
Andreoni, A; Cristofori, GB; Fochi, C; Sganzerla, E, 1981
)
0.26
" When multiple oral or parenteral doses are required, dosing interval should be lengthened or repeated doses reduced below initial doses because of lower systemic clearance."( Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver.
Benowitz, NL; Jacob, P; Pond, SM; Tong, T, 1980
)
0.26
" Buprenorphine showed a bell-shaped dose-response curve in the mouse D'Amour-Smith's test at high stimulus intensity."( [Analgesic and narcotic antagonist effects of buprenorphine (author's transl)].
Hiyama, T; Shintani, S; Tsutsui, M; Yasuda, Y, 1982
)
0.26
" At either of the two dosage levels, pirprofen proved more active than pentazocin."( [A study of the analgesic effects of pirprofen after oral surgery].
Sperr, W, 1982
)
0.26
"The changes in effects on motor activity of rats upon repeated (48 day) dosing with four narcotic analgesics were determined."( Motility response of rats to chronic constant-dose treatment with narcotics.
Davis, WM; Hemnani, KL; Pace, HB, 1982
)
0.26
" 2 The dose-response curves to naloxone obtained in tissues individually exposed to different opiates showed that their relative potency in increasing sensitivity to naloxone was as follows: levorphan greater than morphine greater than Met-enkephalin greater than nalorphine greater than pentazocine."( Pharmacological characterization of opiate physical dependence in the isolated ileum of the guinea-pig.
Luján, M; Rodríguez, R, 1981
)
0.26
"Quantal dose-response curves were generated to determine the median lethal doses (LD50S) for pentazocine and tripelennamine, either alone or in combination."( Potentiation of lethality in mice by combinations of pentazocine and tripelennamine.
Katz, NL; Morris, RW; Waller, DP, 1980
)
0.26
" The control group and the test groups were comparable with regard to biological data, duration of operation, applied dosage of local anaesthetics and actual anxiety before operation."( [Analgesia-sedation for maxillo-facial surgery with midazolam-pentazocine and miazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia].
Daubländer, M; Dick, W; Lipp, M; Sebastian, M, 1995
)
0.29
" Remedication with the same drug at the same dosage was allowed if pain relief was unsatisfactory."( Efficacy and safety of oral tramadol and pentazocine for postoperative pain following prolapsed intervertebral disc repair.
Adriaensen, H; Callebaut, V; Camu, F; Coppejans, H; Debois, V; Kupers, R; Verborgh, C, 1995
)
0.29
"(-)-Pentazocine is active in the tailflick assay in CD-1 mice, although it shows a biphasic dose-response curve with a peak effect of only 30%."( (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system.
Chien, CC; Pasternak, GW, 1995
)
0.29
" This potentiation is dose-dependent at doses between 1 and 1000 micrograms/kg, IV but bell-shaped dose-response curves are obtained."( Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptors.
Bergeron, R; Debonnel, G, 1997
)
0.3
" We have shown that sigma ligands, such as di(2-tolyl)guanidin (DTG), potentiate dose-dependently, with bell-shaped dose-response curves, the neuronal response of pyramidal neurones to N-methyl-D-aspartate (NMDA) in the CA3 region of the rat dorsal hippocampus."( Effect of short-term and long-term treatments with sigma ligands on the N-methyl-D-aspartate response in the CA3 region of the rat dorsal hippocampus.
Bergeron, R; de Montigny, C; Debonnel, G, 1997
)
0.3
" Naloxone (1 microM) or norbinaltorphimine (10 nM) shifted the dose-response curve of (-)-U50,488H to the right by 100-fold."( Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Chen, C; Li, JG; Liu-Chen, LY; Luo, LY; Zhu, J, 1997
)
0.3
" Slopes for dose-response curves were determined."( Effects of nalbuphine, pentazocine and U50488H on gastric emptying and gastrointestinal transit in the rat.
Asai, T; Mapleson, WW; Power, I, 1998
)
0.3
" Patients above 61 years had smaller dosage of pentazocine compared with those in patients under 61 years."( [Anesthetic management by total intravenous anesthesia with propofol, pentazocine and ketamine].
Abe, F; Imamura, M; Masamune, T; Nonaka, A; Suzuki, S, 2005
)
0.33
"From January 2009 to December 2009, sixty patients undergone laminectomy and pedicle internal fixation, who using equal analgesic dosage of Pentazocine and Sulfentanil, were retrospectively analysed."( [Clinical observation of pentazocine for postoperative intravenous analgesia in patients with lumbar herniation].
Jia, R; Xing, JM; Xu, HQ, 2010
)
0.36
"The two groups showed no significant differences in the analgesic effect, dosage of propofol, adverse effects, unconsciousness time, awake time, or hospital stay."( [Application of subclinical doses of pentazocine and propofol in painless vaginal egg retrieval].
Ding, H; Gu, MN; Liang, FG; Shi, YS; Zhou, W, 2011
)
0.37
" This study attempted to clarify the mechanisms underlying such dose-response relationships."( Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice.
An, K; Arita, H; Hanaoka, K; Hayashida, M; Huang, W; Shu, H; Wu, G; Zhang, H, 2011
)
0.37
" Dose-response curves were generally quantal under the FR and graded under the FI schedules, but highly variable among subjects under the FI."( Drug discrimination in pigeons trained to discriminate among morphine, U50488, a combination of these drugs, and saline.
Li, M; McMillan, DE; Wessinger, WD, 2011
)
0.37
"Activation of NRF2 using MMF, at least at our dosing regimen, is insufficient to attenuate catastrophic photoreceptor damage characteristic of rd10 mice."( Comparison of Neuroprotective Effects of Monomethylfumarate to the Sigma 1 Receptor Ligand (+)-Pentazocine in a Murine Model of Retinitis Pigmentosa.
Saul, A; Smith, SB; Wang, J; Xiao, H, 2020
)
0.56
" There was no significant between-group difference in the total pentazocine dosage during the first 7 days (p = 0."( Intra-articular injection versus interscalene brachial plexus block for acute-phase postoperative pain management after arthroscopic shoulder surgery.
Hamada, K; Horishita, T; Kizaki, K; Miyoshi, S; Nakayama, K; Uchida, S; Utsunomiya, H, 2023
)
0.91
"Strict adherence to pharmacological dosage regimens is a prerequisite to the success of most treatments, particularly for patients in drug abuse programs."( Urinalysis based assessment of compliance and drug use patterns in patients prescribed tramadol: A cross-sectional study from a tertiary care centre.
Ghosh, S; Jain, R; Saifi, N; Sarkar, S, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzazocine
benzazocine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Pentazocine Action Pathway3111

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)Ki0.00390.00000.419710.0000AID1718175
Kappa-type opioid receptorHomo sapiens (human)Ki0.00220.00000.362410.0000AID1718176
Sigma intracellular receptor 2Homo sapiens (human)Ki1.60330.00010.83604.6005AID1655661; AID1718134; AID1861724
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)Ki1.46500.00241.10509.3000AID1877931
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.00520.00000.338510.0000AID1679115; AID1728274; AID1744232; AID1759953; AID1824522; AID1867871; AID1877932; AID1901074; AID1901323
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.00840.00000.490110.0000AID1718132; AID1861723
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.00540.00000.27869.0000AID1363621
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.00540.00000.338510.0000AID1363621
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Kd0.00290.00200.20160.6000AID1597432
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (51)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
regulation of cell growthSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular lipid transportSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular cholesterol transportSigma intracellular receptor 2Homo sapiens (human)
cholesterol homeostasisSigma intracellular receptor 2Homo sapiens (human)
positive regulation of wound healingSigma intracellular receptor 2Homo sapiens (human)
positive regulation of lipoprotein transportSigma intracellular receptor 2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
protein bindingSigma intracellular receptor 2Homo sapiens (human)
oxysterol bindingSigma intracellular receptor 2Homo sapiens (human)
cholesterol bindingSigma intracellular receptor 2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
lysosomeSigma intracellular receptor 2Homo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
plasma membraneSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulum membraneSigma intracellular receptor 2Homo sapiens (human)
nuclear membraneSigma intracellular receptor 2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1901323Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane by competitive radioligand receptor binding assay
AID1718132Binding affinity to sigma-1 receptor (unknown origin)2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1877932Displacement of [3H]-(+)-pentazocine from Dunkin-Hartley guinea pig brain cortex Sigma 1 receptor incubated for 150 mins by liquid scintillation counting analysis2022European journal of medicinal chemistry, Feb-15, Volume: 230Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation.
AID1867871Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes measured after 120 mins by scintillation counting method2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of conformationally restricted GluN2B ligands derived from eliprodil.
AID1728274Displacement of [3H]-pentazocine from sigma1 receptor in guinea pig brain membrane incubated for 120 mins by liquid scintillation counting method2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel σ
AID1655661Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor (unknown origin) incubated for 1 hr in presence of (+)SKF10047 by liquid scintillation counting method
AID1861728Binding affinity to KOR (unknown origin) assessed as inhibition constant by radioligand binding assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1901074Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane measured by competitive radioligand receptor binding assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Synthesis of 8-aminomorphans with high KOR affinity.
AID1861724Binding affinity to sigma 2 receptor (unknown origin) assessed as inhibition constant by radioligand binding assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1679115Displacement of [3H]-pentazocine from guinea pig brain sigma 1 receptor incubated for 120 mins by liquid scintillation counting method2021RSC medicinal chemistry, Mar-04, Volume: 12, Issue:2
Synthesis and
AID1655660Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membranes incubated for 1 hr by liquid scintillation counting method
AID1744232Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain membranes incubated for 1 hr by liquid scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1759953Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane measured after 120 mins by solid scintillation counting method
AID1824522Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membranes measured after 120 mins by scintillation counting method2022European journal of medicinal chemistry, Jan-15, Volume: 228Development of novel phenoxyalkylpiperidines as high-affinity Sigma-1 (σ
AID1718175Binding affinity to mu opioid receptor (unknown origin)2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1877931Displacement of [3H]-DTG from Sprague-Dawley rat liver Sigma 2 receptor incubated for 120 mins in presence of [3H]-(+)-pentazocine by liquid scintillation counting analysis2022European journal of medicinal chemistry, Feb-15, Volume: 230Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation.
AID1861723Binding affinity to sigma 1 receptor (unknown origin) assessed as inhibition constant by radioligand binding assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1861726Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1861727Binding affinity to DOR (unknown origin) assessed as inhibition constant by radioligand binding assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1718134Binding affinity to sigma-2 receptor (unknown origin)2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1861725Selectivity index, ratio of Ki for sigma 1 receptor (unknown origin) to Ki for sigma 2 receptor (unknown origin)2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1718176Binding affinity to kappa opioid receptor (unknown origin)2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1346329Human kappa receptor (Opioid receptors)1997The Journal of pharmacology and experimental therapeutics, Aug, Volume: 282, Issue:2
Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
AID1346329Human kappa receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346364Human mu receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346361Human delta receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1406153Displacement of (+)-[3H]pentazocine from guinea pig brain membrane sigma1 receptor by liquid scintillation counting method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID1420188Cytotoxicity against human PANC1 cells at 50 uM after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation.
AID1363621Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes incubated for 120 mins by scintillation counting method2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety.
AID1574666Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membranes after 120 mins by scintillation counting method2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.
AID1597432Binding affinity to sigma1 receptor in Hartley guinea pig brain cortex membranes incubated for 150 mins by liquid scintillation counting method
AID1420180Cytotoxicity against human SH-SY5Y cells at 50 uM after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,089)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901464 (70.08)18.7374
1990's311 (14.89)18.2507
2000's155 (7.42)29.6817
2010's128 (6.13)24.3611
2020's31 (1.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 95.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index95.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index163.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (95.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials353 (15.61%)5.53%
Trials0 (0.00%)5.53%
Reviews71 (3.14%)6.00%
Reviews0 (0.00%)6.00%
Case Studies169 (7.47%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (0.04%)0.25%
Observational0 (0.00%)0.25%
Other1,668 (73.74%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of a Kappa Agonist on Hot Flashes in Menopausal Women [NCT02070718]Phase 112 participants (Actual)Interventional2013-01-31Completed
[NCT02208596]Phase 4150 participants (Anticipated)Interventional2014-09-30Not yet recruiting
Single-centre, Randomized, Clinical Trial of Opioid-free Analgesia Versus Routine Opioid-based Analgesia Regimen for the Management of Acute Post-operative Pain Following Caesarean Section [NCT04539249]324 participants (Actual)Interventional2020-11-04Completed
Pain Treatment in Posterior Thoracolumbar Operation a Randomized Study to Assess the Effect of Local Analgesia After Operation [NCT01872494]Phase 471 participants (Actual)Interventional2013-05-31Completed
Effects of Pentazocine Versus Lorazepam on Manic Symptoms [NCT00431184]Phase 219 participants (Actual)Interventional2007-01-31Completed
Inpatient Clinical Trial Examining the Effects of Pentazocine on Manic Symptoms [NCT00125931]Phase 210 participants (Actual)Interventional2005-09-30Completed
Outcome of Combined Tramadol and Paracetamol Versus Pentazocine as Labour Analgesia Among Parturients in the Federal Medical Center, Yenagoa, Bayelsa State, Southern Nigeria: A Randomized Controlled Trial [NCT05565274]166 participants (Anticipated)Interventional2022-10-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00125931 (2) [back to overview]Mania Symptoms Using MACS
NCT00125931 (2) [back to overview]YMRS Scores
NCT00431184 (2) [back to overview]Mania Acute Rating Scale (MACS)
NCT00431184 (2) [back to overview]Young Mania Rating Scale (YMRS)
NCT04539249 (9) [back to overview]Mean Dose of Pentazocine Used
NCT04539249 (9) [back to overview]Post-operative Pain Scores Following Caesarean Section at 24 Hours Post-operative
NCT04539249 (9) [back to overview]Post-operative Pain Scores Following Caesarean Section at 4 Hours Post-operative
NCT04539249 (9) [back to overview]Post-operative Pain Scores Following Caesarean Section at 8 Hours Post-operative
NCT04539249 (9) [back to overview]Frequency and Nature of Pentazocine Use
NCT04539249 (9) [back to overview]Pentazocine Use as Rescue Analgesia
NCT04539249 (9) [back to overview]Post-operative Pentazocine Use
NCT04539249 (9) [back to overview]Apgar Scores of the Neonates
NCT04539249 (9) [back to overview]Number of Participants With Peri-operative Adverse Events

Mania Symptoms Using MACS

Assessment of current mania symptoms using Mania Acute Change Scale (MACS). All 20 questions on the scale have a 0 (absent)-4(most severe) range for describing mania symptoms. The mean MACS score totals were reported, with the total ranging from 0-80. A higher total score indicates a greater number of symptoms and higher symptom intensity, while a smaller score indicates a lesser number of symptoms and higher lower intensity. (NCT00125931)
Timeframe: hourly for 6 hours after first dose of pentazocine; hour 0 is the baseline score and also when first dose of pentazocine was administered

Interventionunits on a scale (Mean)
Hour 2Hour 3
Open Label Group18.611.0

[back to top]

YMRS Scores

Assessment of current mania symptoms using YMRS. All questions have a 0 (absent)-4(most severe) range for describing mania symptoms. The mean YMRS scores were reported, with the total ranging from 0-44. A higher total score indicates a greater number of symptoms and higher symptom intensity, while a smaller score indicates a lesser number of symptoms and higher lower intensity. (NCT00125931)
Timeframe: Each morning of the three-day study

Interventionunits on a scale (Mean)
pre-treatment daytreatment daypost-treatment day
Open Label Group23.622.012.7

[back to top]

Mania Acute Rating Scale (MACS)

Assessment of current mania symptoms using Mania Acute Change Scale (MACS). All 20 questions on the scale have a 0 (absent)-4(most severe) range for describing mania symptoms. The mean MACS score totals were reported, with the total ranging from 0-80. A higher total score indicates a greater number of symptoms and higher symptom intensity, while a smaller score indicates a lesser number of symptoms and higher lower intensity. The change in MACS scores from baseline and those following treatment administration were averaged. The number below represents the average mean change. (NCT00431184)
Timeframe: On Day 1 and Day 2, at the time of administration of intervention and 5 hours following administration of intervention

Interventionunits on a scale (Mean)
Pentazocine3.9
Lorazepam6.4

[back to top]

Young Mania Rating Scale (YMRS)

The YMRS is used to assess manic symptoms. There are 11 questions which ask the patient to rate the severity of symptoms. Scores range from 0 to a maximum of 60. All questions are rated based on severity, with a higher score signifying increased severity. Questions 1-4, 7, and 10 are rated on a 0-4 scale. Questions 5, 6, 8, and 9 are rated on a 0-8 scale. (NCT00431184)
Timeframe: at the time of administration of intervention and 5 hours following administration of intervention

Interventionunits on a scale (Mean)
Pentazocine23.0
Lorazepam22.6

[back to top]

Mean Dose of Pentazocine Used

Mean dose of Pentazocine used in each arm of the study (NCT04539249)
Timeframe: 24 hours post-operative

InterventionMilligrams (Mean)
Magnesium Sulphate52.83
Pentazocine164.40

[back to top]

Post-operative Pain Scores Following Caesarean Section at 24 Hours Post-operative

Post-operative pain scores following caesarean section at 24 hours post-operative using the Numerical Rating Scale for pain. The Numerical Rating Scale for pain has a minimum score of 0, a maximum score of 10 and a range of 0-10, where higher scores mean a worse outcome (0= No pain at all, 5= Moderate pain and 10= Worst pain imaginable) (NCT04539249)
Timeframe: 24 hours post-operative

Interventionscore on a scale (Mean)
Magnesium Sulphate2.06
Pentazocine2.37

[back to top]

Post-operative Pain Scores Following Caesarean Section at 4 Hours Post-operative

Post-operative pain scores following caesarean section at 4 hours post-operative using the Numerical Rating Scale for pain. The Numerical Rating Scale for pain has a minimum score of 0, a maximum score of 10 and a range of 0-10, where higher scores mean a worse outcome (0= No pain at all, 5= Moderate pain and 10= Worst pain imaginable) (NCT04539249)
Timeframe: 4 hours post-operative

Interventionscore on a scale (Mean)
Magnesium Sulphate2.98
Pentazocine3.16

[back to top]

Post-operative Pain Scores Following Caesarean Section at 8 Hours Post-operative

Post-operative pain scores following caesarean section at 8 hours post-operative using the Numerical Rating Scale for pain. The Numerical Rating Scale for pain has a minimum score of 0, a maximum score of 10 and a range of 0-10, where higher scores mean a worse outcome (0= No pain at all, 5= Moderate pain and 10= Worst pain imaginable) (NCT04539249)
Timeframe: 8 hours post-operative

Interventionscore on a scale (Mean)
Magnesium Sulphate2.58
Pentazocine2.68

[back to top]

Frequency and Nature of Pentazocine Use

Frequency of Pentazocine use per participant in each arm of the study and whether it was used as indicated in the protocol and/or for rescue analgesia (NCT04539249)
Timeframe: 24 hours post-operative

,
InterventionParticipants (Count of Participants)
More than 4 times (per protocol + as rescue analgesia)Four times (per protocol)Four times (as rescue analgesia)Three times (as rescue analgesia)Two times (as rescue analgesia)Once (as rescue analgesia)Not used at all
Magnesium Sulphate000011354
Pentazocine05000000

[back to top]

Pentazocine Use as Rescue Analgesia

Whether or not pentazocine was used as rescue analgesia (NCT04539249)
Timeframe: 24 hours post-operative

,
InterventionParticipants (Count of Participants)
Pentazocine used as rescue analgesiaPentazocine NOT used as rescue analgesia
Magnesium Sulphate464
Pentazocine050

[back to top]

Post-operative Pentazocine Use

Whether or not Pentazocine was used post-operatively (NCT04539249)
Timeframe: 24 hours post-operative

,
InterventionParticipants (Count of Participants)
Pentazocine usedPentazocine NOT used
Magnesium Sulphate464
Pentazocine500

[back to top]

Apgar Scores of the Neonates

Apgar scores of the neonates delivered by the women who had caesarean section under the study, taken at first and fifth minutes after birth. Apgar score has a minimum score of 0, a maximum score of 10 and a range of 0-10, where higher scores mean a better outcome (0-3= low Apgar score, 4-6= moderately abnormal Apgar score and 7-10= reassuring Apgar score (NCT04539249)
Timeframe: At first and fifth minutes after birth

InterventionParticipants (Count of Participants)
Apgar score at the 1st minute72410061Apgar score at the 1st minute72410060Apgar score at the 5th minute72410061Apgar score at the 5th minute72410060
4-6Less than 47-10
Pentazocine0
Magnesium Sulphate2
Pentazocine6
Magnesium Sulphate48
Pentazocine44
Magnesium Sulphate0
Pentazocine1
Magnesium Sulphate50
Pentazocine49

[back to top]

Number of Participants With Peri-operative Adverse Events

Number of participants with peri-operative adverse events including hypersensitivity reaction, respiratory depression, bradycardia, hypotension, nausea and vomiting, lightheadedness, presyncope, and any other adverse event recorded from the time of first administration of peri-operative analgesia to 2 hours postoperative (NCT04539249)
Timeframe: Time of first administration of peri-operative analgesia to 2 hours postoperative

InterventionParticipants (Count of Participants)
Bradycardia72410060Bradycardia72410061Systolic hypotension72410060Systolic hypotension72410061Severe (Symptomatic) systolic hypotension72410060Severe (Symptomatic) systolic hypotension72410061Diastolic hypotension72410060Diastolic hypotension72410061Severe (Symptomatic) diastolic hypotension72410060Severe (Symptomatic) diastolic hypotension72410061Vomiting72410060Vomiting72410061Lightheadedness72410060Lightheadedness72410061Presyncope72410060Presyncope72410061
AbsentPresent
Magnesium Sulphate0
Pentazocine2
Magnesium Sulphate50
Pentazocine48
Magnesium Sulphate14
Pentazocine5
Magnesium Sulphate36
Pentazocine45
Magnesium Sulphate13
Magnesium Sulphate24
Pentazocine18
Magnesium Sulphate26
Pentazocine32
Magnesium Sulphate23
Magnesium Sulphate1
Magnesium Sulphate49
Pentazocine50
Pentazocine0

[back to top]